Results 131 to 140 of about 2,808,091 (266)

Correction to: DEGRO statement on the KEYNOTE-689 trial: Perioperative immunotherapy in combination with adjuvant (chemo-)radiotherapy for resectable locally advanced head and neck cancers. [PDF]

Strahlenther Onkol
Schnellhardt S, Böke S, Tribius S, Krause M, Haderlein M, Rühle A, Süß C, Linge A, Hecht M, Balermpas P, Head and Neck Cancer Expert Panel of the German Society of Radiation Oncology DEGRO.   +10 more
europepmc   +1 more source

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach, Gizem Abaci, Tom Huberty, Axel Lechner, Lukas Käsmann, Jens Ricke, Sophia Stöcklein, Martin Canis, Philipp Baumeister, Marianna Alunni‐Fabbroni   +9 more
wiley   +1 more source

All‑cause excess mortality in Germany peaked during the late‑2022 influenza period, exceeding peaks during SARS‑CoV‑2 waves (2020-2023). [PDF]

PLoS One
Heudorf U, Kowall B.
europepmc   +1 more source

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

Molecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang, Hyung Seok Kim, Geum Ok Baek, Moon Gyeong Yoon, Su In Lee, Jee‐Yeong Jeong, Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun   +9 more
wiley   +1 more source

German law on protection of children with DSD: first data on care after enactment. [PDF]

Endocr Connect
Neumann U, Binder G, Eckoldt F, Döhnert U, Dunstheimer D, Holterhus PM, Ludwikowski B, Wabitsch M, Woelfle J, Richter-Unruh A, Kamrath C.   +10 more
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

Grundsätzlich besser? Finnlands nationale Konzepte, Strategien und Empfehlungen für Bibliotheken

Library Ideas, 2020
Sari Herde
doaj   +1 more source

Correction: Decreased spinal inhibition leads to undiversified locomotor patterns. [PDF]

Biol Cybern
de Graaf ML, Wagner H, Mochizuki L, Le Mouel C.   +3 more
europepmc   +1 more source

Tuberculosis in Germany [PDF]

Proceedings of the National Academy of Sciences, 1948
openaire   +3 more sources

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source